3D Medicines   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Minhang China (2010)

Organization Overview

First Clinical Trial
2017
NCT02827968
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

3D Medicines | 3D Medicines (Beijing) Co., Ltd. | 3D Medicines (Sichuan) Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Tract Neoplasms (Phase 3)

Carcinoma, Hepatocellular (Phase 1)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 14